

1 SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody
2 magnitude is associated with age and COVID-19 severity

3
4 Eric D. Laing, PhD^{1†}, Nusrat J. Epsi, PhD^{2,3†}, Stephanie A. Richard, PhD^{2,3}, Emily C. Samuels,
5 BS^{1,3}, Wei Wang, PhD⁴, Russell Vassell, MS⁴, Daniel F. Ewing, PhD⁵, Rachel Herrup⁴, Spencer
6 L. Sterling, MPH^{1,3}, David A Lindholm, MD⁶, Eugene V. Millar, PhD^{2,3}, Ryan C. Maves, MD⁷,
7 Derek T. Larson, DO⁸, Rhonda E. Colombo, MD^{2,3,9}, Sharon Chi, DO¹⁰, Cristian Madar, MD¹⁰,
8 Tahaniyat Lalani, MBBS¹¹, Anuradha Ganesan, MBBS^{2,3,12}, Anthony Fries, PhD¹³, Christopher J.
9 Colombo, MD⁹, Katrin Mende, PhD^{2,3,6}, Mark P. Simons, PhD^{1,2}, Kevin L. Schully, PhD⁵, Carol
10 D. Weiss, PhD⁴, David R. Tribble, MD², Brian K. Agan, MD^{2,3}, Simon D. Pollett, MBBS^{2,3},
11 Christopher C. Broder, PhD¹, and Timothy H. Burgess, MD^{*2} for the EPICC Study Team

12
13 ¹Department of Microbiology and Immunology, Uniformed Services University of the Health
14 Sciences, Bethesda, MD, USA

15 ²Infectious Disease Clinical Research Program, Department of Preventive Medicine and
16 Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

17 ³Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD
18 USA

19 ⁴Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring,
20 MD, USA

21 ⁵Biological Defense Research Directorate, Naval Medical Research Center-Fort Detrick,
22 Frederick, MD, USA

23 ⁶Brooke Army Medical Center, Fort Sam Houston, TX, USA

24 ⁷Naval Medical Center San Diego, San Diego, CA, USA

25 ⁸Fort Belvoir Community Hospital, Fort Belvoir, VA, USA

26 ⁹Madigan Army Medical Center, Joint Base Lewis-McChord, WA

27 ¹⁰Tripler Army Medical Center, Honolulu, HI, USA

28 ¹¹Naval Medical Center Portsmouth, Portsmouth, VA, USA

29 ¹²Walter Reed National Military Medical Center, Bethesda, MD

30 ¹³U.S. Air Force School of Aerospace Medicine, Dayton, Ohio, USA

31
32 †Denotes equal contribution

33

34 *Correspondence

35 T. H. Burgess, MD, MPH, FACP

36 Captain, Medical Corps, U.S. Navy

37 Director, Infectious Diseases Clinical Research Program

38 Associate Professor, Department of Preventive Medicine and Biostatistics

39 Uniformed Services University (USU)

40 office +1 301-295-1579 mobile +1 301-221-0399

41 email timothy.burgess@usuhs.edu

42

43

44

45 **ABSTRACT**

46 **Importance:** The persistence of SARS-CoV-2 antibodies may be a predictive correlate of
47 protection for both natural infections and vaccinations. Identifying predictors of robust antibody
48 responses is important to evaluate the risk of re-infection / vaccine failure and may be
49 translatable to vaccine effectiveness.

50 **Objective:** To 1) determine the durability of anti-SARS-CoV-2 IgG and neutralizing antibodies in
51 subjects who experienced mild and moderate to severe COVID-19, and 2) to evaluate the
52 correlation of age and IgG responses to both endemic human seasonal coronaviruses (HCoVs)
53 and SARS-CoV-2 according to infection outcome.

54 **Design:** Longitudinal serum samples were collected from PCR-confirmed SARS-CoV-2 positive
55 participants (U.S. active duty service members, dependents and military retirees, including a
56 range of ages and demographics) who sought medical treatment at seven U.S. military hospitals
57 from March 2020 to March 2021 and enrolled in a prospective observational cohort study.

58 **Results:** We observed SARS-CoV-2 seropositivity in 100% of inpatients followed for six months
59 (58/58) to one year (8/8), while we observed seroreversion in 5% (9/192) of outpatients six to
60 ten months after symptom onset, and 18% (2/11) of outpatients followed for one year. Both
61 outpatient and inpatient anti-SARS-CoV-2 binding-IgG responses had a half-life ($T_{1/2}$) of >1000
62 days post-symptom onset. The magnitude of neutralizing antibodies (geometric mean titer,
63 inpatients: 378 [246-580, 95% CI] versus outpatients: 83 [59-116, 95% CI]) and durability
64 (inpatients: 65 [43-98, 95% CI] versus outpatients: 33 [26-40, 95% CI]) were associated with
65 COVID-19 severity. Older age was a positive correlate with both higher IgG binding and
66 neutralizing antibody levels when controlling for COVID-19 hospitalization status. We found no
67 significant relationships between HCoV antibody responses and COVID-19 clinical outcomes, or
68 the development of SARS-CoV-2 neutralizing antibodies.

69 **Conclusions and Relevance:** This study demonstrates that humoral responses to SARS-CoV-
70 2 infection are robust on longer time-scales, including those arising from milder infections.

71 However, the magnitude and durability of the antibody response after natural infection was
72 lower and more variable in younger participants who did not require hospitalization for COVID-
73 19. These findings support vaccination against SARS-CoV-2 in all suitable populations including
74 those individuals that have recovered from natural infection.

75

76 **INTRODUCTION**

77 The immune correlates of protection against severe acute respiratory syndrome
78 coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) are unknown.
79 However, the development of detectable humoral immunity is likely a predictive surrogate of
80 protection^{1,2}. The presence of broadly neutralizing serum antibodies five to eight months after
81 SARS-CoV-2 infection have been documented by several groups³⁻¹⁰. Cases of symptomatic
82 COVID-19 following re-infection with SARS-CoV-2 have been reported but are infrequent¹¹⁻¹⁵,
83 and recent studies have highlighted a correlation between the presence of SARS-CoV-2
84 antibodies and decreased risk of reinfections^{16,17}.

85 The magnitude of the antibody response to SARS-CoV-2 infection has been positively
86 correlated with COVID-19 severity¹⁸⁻²⁵, but the confounding effect of age on this association
87 remains unresolved²⁶⁻²⁸. Even less understood is whether cross-reactive seasonal human
88 coronavirus (HCoV) antibodies correlate with the kinetics of SARS-CoV-2 humoral responses
89 across acute and post-acute timescales after SARS-CoV-2 infection²⁹⁻³². Pre-existing HCoV
90 antibodies that cross-react with but do not cross-neutralize SARS-CoV-2 have been
91 detected^{30,33-36}, and recent infection with HCoVs has been correlated with reduced COVID-19
92 severity³⁷.

93 Here, we demonstrate the persistence of SARS-CoV-2 IgG binding and neutralizing
94 responses out to twelve months in participants enrolled in a prospective study at seven military
95 treatment facilities (MTFs) across the U.S. from March 2020 to March 2021. MTFs provide care
96 for active duty servicemembers, dependents and military retirees, including a range of ages and

97 demographics that is broadly representative of the civilian U.S. population. Study participants
98 were followed for up to twelve months allowing analyses to identify correlates of long humoral
99 immune durability to SARS-CoV-2. The aims are to (i) describe the magnitude and durability of
100 SARS-CoV-2 antibody response for one year after natural infection, and (ii) identify correlates of
101 SARS-CoV-2 antibody response, including COVID-19 severity, age, and antibody profiles to
102 HCoVs.

103

104 **METHODS**

105 *Study population, setting, participant enrollment and sera collection*

106 Participants were enrolled and serum samples were collected in the Epidemiology,
107 Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic
108 Potential (EPICC) protocol: a prospective, longitudinal study of COVID-19. The protocol was
109 approved by the Uniformed Services University Institutional Review Board (IDCRP-085), and all
110 subjects or their legally authorized representative provided informed consent to participate.
111 Participants were enrolled at seven MTFs across the United States, including Walter Reed
112 National Military Medical Center (Bethesda, MD), Brooke Army Medical Center (San Antonio,
113 TX), Naval Medical Center San Diego (San Diego, CA), Naval Medical Center Portsmouth
114 (Portsmouth, VA), Madigan Army Medical Center (Tacoma, WA), Fort Belvoir Community
115 Hospital (Fort Belvoir, VA) and Tripler Army Medical Center (Honolulu, HI). Eligible participants
116 included individuals with laboratory-confirmed SARS-CoV-2 infection by nucleic acid
117 amplification test (NAAT), individuals with SARS-CoV-2-like illness, and individuals who were
118 tested following a high risk exposure to a SARS-CoV-2 positive person or screening
119 surrounding travel. Blood specimens were collected at enrollment, and then at seven, fourteen,
120 and twenty-eight days, and subsequently at three, six and twelve months after enrollment.

121 Antibody results from SARS-CoV-2 PCR-positive (n=505) and SARS-CoV-2 PCR-
122 negative (n=92) participants were included in the evaluation of humoral response to SARS-CoV-

123 2 infection. From these participants, we analyzed spike protein IgG binding in a serial collection
124 of 764 serum samples from 250 (outpatients n= 192, inpatients n= 58) participants who were
125 followed through six and twelve months-post-enrollment. Six months serum samples from these
126 participants were collected at a median 188 days post-symptom onset (dpso), IQR= 15. Of
127 these 250 participants, 19 (outpatients, n= 11; inpatients= 8) had available sera drawn twelve
128 months from the onset of symptoms and prior to vaccination, allowing long-term monitoring of
129 IgG duration (eFigure 1). Serum samples collected from individuals after the administration of
130 COVID-19 vaccinations were excluded from this analysis of antibody responses to natural
131 infection. To characterize the durability of the neutralizing antibody response to SARS-CoV-2,
132 paired sera from 72 participants who had serum samples collected during early convalescence
133 (median 36 dpso, IQR= 14.50) and at six months-post symptom onset collected from
134 September to October 2020 were evaluated by a SARS-CoV-2 S-pseudovirus neutralization test
135 (SNT) and an authentic wild-type SARS-CoV-2 virus neutralization test (VNT). Twelve months-
136 post sera collected in March 2021 from 7 inpatients and 4 outpatients were further evaluated by
137 SNT.

138

139 *Multiplex microsphere-based immunoassay screening procedures*

140 Detailed experimental procedures of SARS-CoV-2 and HCoV spike protein-based
141 multiplex microsphere immunoassays have been previously described³⁸⁻⁴⁰ and are described
142 further in the Supplementary Appendix (eMethods). Briefly, diluted serum and capillary blood
143 samples were tested in technical duplicates. Antigen-antibody complexes were analyzed on Bio-
144 Plex 200 multiplexing systems (Bio-Rad, Hercules, CA) for IgG binding and median
145 fluorescence intensity (MFI) values are reported.

146

147 *SARS-CoV-2 S-pseudovirus production and neutralization (SNT)*

148 The spike (S) sequence from SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank accession:
149 YP_009724390.1) was used to construct lentiviral pseudoviruses for the neutralization assays,
150 as described previously⁴¹. Additional details are provided in the (eMethods), briefly, pseudovirus
151 titers were measured by infecting 293T-ACE2.TMPRSS2 cells. Pseudovirus titers were
152 determined as relative luminescence units per milliliter of pseudovirus supernatants (RLU/ml).
153 The antibody dilution causing a 50% and 80% reduction (inhibitory concentration, IC) of vector-
154 expressed luciferase compared to control (IC₅₀- and IC₈₀-neutralizing antibody titer, respectively)
155 was calculated with nonlinear regression using GraphPad Prism. Data reported were averages
156 from at least two independent experiments.

157

158 *Wild-type SARS-CoV-2 plaque reduction neutralization tests (VNT)*

159 VNT antibody titers were determined by plaque reduction neutralization test (PRNT) as
160 previously described with modifications⁴². Details of experimental procedures are included in the
161 Supplementary Appendix (eMethods). SARS-CoV-2 (USA WA1/2020, BEI Resources cat # NR-
162 52281) and serum samples were incubated for one hour then incubated with Vero-81 cells
163 (ATCC cat NoCRL-1587). Cutoffs for 80% PRNT titers (PRNT₈₀) were determined on each plate.
164 Wells with an OD₄₀₅ less than 20% of the mean value of nine virus only controls, plus one
165 standard deviation, were considered neutralizing.

166

167 *Statistical analysis of humoral response correlates*

168 Log-scale transformations were applied to all SARS-CoV-2 IgG binding and
169 neutralization antibody datasets to explore normality and parametric or non-parametric were
170 applied as indicated. For VNT PRNT80 titers, zero values were changed to 0.01 prior to log10-
171 transformation and nonparametric unpaired Mann-Whitney tests were performed. Generally,
172 second order polynomial curves were the preferred non-linear regression model ($\alpha = 0.05$) and
173 these best-fit curves with confidence intervals are shown in all graphs. Exponential phase-decay

174 analyses were used to explore antibody half-life ($T_{1/2}$) trends utilizing subjects with ≥ 2
175 longitudinal sera samples, and, based on best-fit, either a one-phase or two-phase decay model
176 was preferred. When single models for all the datasets were not preferred or a best-fit single
177 curve was ambiguous, a robust fit without curve fitting was applied and the mean of all subjects'
178 individual $T_{1/2}$ was calculated; in several instances $T_{1/2}$ exceeded 1000 days and were reported
179 as >1000 . We used Brown-Forsythe and Welch's ANOVA to compare age-stratified log10-
180 transformed IgG binding MFI data and adjusted for multiple comparisons through use of the
181 Dunnet's multiple T3 comparison test. Box-Cox transformations were applied to HCoV IgG
182 binding MFI values to normalize the data and parametric t-tests were performed. Multivariate
183 linear regression models were used to compare MFI among age groups and by hospitalization
184 status (with interaction term), and separate models were run for samples collected in the early
185 convalescence period and at six months-post. Figures were generated and statistical analyses
186 were performed in GraphPad Prism version 9.0.2 and RStudio version 4.0.2 software (R
187 Foundation for Statistical Computing)⁴³.

188

189 **RESULTS**

190 *Demographic and hospitalization status of EPICC participants*

191 Over half of the participants were 18-44 years of age or male. The racial distribution of
192 participants was non-Hispanic white (44.3%), followed by Hispanic (31.2%) and African-
193 American (14.1%) (Table 1). Participants were classified according to the maximum severity
194 reported during follow-up as hospitalized (inpatients) or outpatients. Participants were stratified
195 into three age groups: 18-44, >44 -64 and ≥ 65 years old. The median age of inpatient and
196 outpatient participants was 58.2 (interquartile range (IQR)= 16.3 years) and 43.3 (IQR= 24.4)
197 years, respectively.

198

199

200 *SARS-CoV-2 binding and neutralizing antibody responses differ by COVID-19 severity*

201 We observed 95% (183/192) of outpatients and 100% of inpatients (58/58) remained
202 seropositive at six months-post, and 9/11 outpatients and 8/8 inpatients remained seropositive
203 at 12 months-post symptom onset. A one-phase decay of the IgG response of inpatients
204 calculated a $T_{1/2} > 1000$ days (Figure 1A). IgG responses displayed greater heterogeneity
205 among outpatients than inpatients and a one-phase decay curve modeled a $T_{1/2} = 1232$ days
206 (Figure 1A). Next, we sought to investigate whether the magnitude or duration of the IgG
207 response was associated with COVID-19 clinical disease severity as determined by
208 hospitalization status. For this analysis, magnitude was explored as IgG responses recorded
209 during early convalescence for each participant across all longitudinal sera collections and the
210 durability of the antibody response was assessed with sera collected six and twelve months-
211 post symptom onset. Geometric mean IgG levels during early convalescence and six months-
212 post-infection were significantly higher in inpatients than in outpatients (early convalescence:
213 inpatients= 27,646 MFI [95% Confidence Interval (CI): 26,688-28,639], outpatients= 20,587 MFI
214 [CI:19,057-22,241], $P < 0.001$; six months-post-infection: inpatients= 22,694 MFI [95% CI:
215 19,967-25,792], outpatients= 13,559 MFI [95% CI: 12,343-14,895], $P < 0.001$) (Figure 1B). By
216 twelve months-post we found no differences in geometric mean IgG binding between inpatients
217 (14,755 [95% CI: 11,181-19,472]) and outpatients (10,588 [95% CI: 6,421-17,460]) ($P = 0.78$). In
218 addition to MFI as a measurement of IgG binding, we determined anti-SARS-CoV-2 IgG
219 endpoint titers. Again, we found that the geometric mean of endpoint titers (GMT) were
220 significantly higher for inpatients than outpatients during early convalescence (inpatients=
221 13,029 [95% CI: 9375-18,108], outpatients= 3240 [95% CI: 2323-4518]) (eFigure 2A), and six
222 months-post (inpatients= 8268 [95% CI: 5323-12,843], outpatients= 2216 [95% CI: 1654-2970])
223 (eFigure 2B).

224 Next, sera were assessed for neutralizing antibodies by SNT; IC_{80} titers are shown in
225 Figures 1 and 2, while IC_{50} titers are provided in eFigure 3A-C. A one-phase decay modeled

226 inpatient $T_{1/2}$ neutralizing antibody responses of 88 days and a two-phase decay of outpatient
227 neutralizing antibody responses calculated a mean fast/slow- $T_{1/2}$ of 77/132 days (Figure 1C).
228 The neutralizing antibody GMT was greater for inpatients than outpatients during both early
229 convalescence, 378 [95% CI: 246-580] versus 83 [95% CI: 59-116] ($P < 0.001$), and six months-
230 post, 65 [95% CI: 43-98] versus 33 [95% CI: 26-40] ($P = 0.006$), although these differences were
231 not observed by twelve months-post (Figure 1D). These significant associations between
232 COVID-19 severity, and IC_{80} neutralizing antibody kinetics and durability were also observed
233 with IC_{50} titers (eFigure 3A-C).

234 Recapitulating the durability, magnitude, and correlates of humoral immune response to
235 SARS-CoV-2 across different populations with different neutralization assays remains a critical
236 goal⁴⁴. Antibody neutralization was further characterized by a wild-type SARS-CoV-2 VNT.
237 Endpoint titers in VNT correlated significantly and had a modest coefficient strength with SNT
238 titers (Spearman's $\rho = 0.77$, $P < 0.001$) (eFigure 4A). A one-phase decay of VNT neutralizing
239 antibody responses calculated a $T_{1/2}$ of 106 and 29 days for inpatients and outpatients,
240 respectively (eFigure 4B-C). The magnitude and durability of VNT GMT was also different
241 between inpatients and outpatients during early convalescence (inpatients=52 [95% CI: 14-198],
242 outpatients=11 [95% CI: 4-29], $P < 0.001$) and six months-post (inpatients=14 [95% CI: 3-71],
243 outpatients=2 [95% CI: 0.5-5], $P = 0.02$) (eFigure 4D).

244

245 *Age correlation with antibody durability may be explained by age-specific clinical severity*

246 Because age is associated with hospitalization status, we used a multivariate regression
247 model to explore antibody magnitude and durability on the basis of COVID-19 severity and age
248 (groups: 18-44, >44-64, and ≥ 65 -years-old). This analysis revealed that during early
249 convalescence IgG levels were higher for all inpatient participants, and increased with age for
250 outpatients with significantly higher IgG-binding levels in ≥ 65 -years-old outpatients that was
251 comparable to ≥ 65 -years-old inpatients (Figure 2A). Furthermore, significant differences in IgG-

252 binding levels were noted between outpatients in 18-44-years-old (19,124 MFI [95% CI: 17,058-
253 21,439, $P < 0.001$) and >44-64-years-old groups (20,897 MFI [95% CI: 18,404-23,728], P
254 <0.001) compared to the ≥ 65 -years-old group (27,703 MFI [95% CI: 26,401-29,069]) (Figure
255 2B). By six months-post, IgG levels remained higher for inpatients across age groups than the
256 outpatients (Figure 2C), and significantly so for the >44-64-years-old (24,789 MFI [95% CI:
257 22,947-26,779], $P = 0.019$) compared to the 18-44 years-old age group (Figure 2D). Additionally,
258 no differences in the IgG response were detected by twelve months-post (eFigure 5A). The IgG
259 $T_{1/2}$ of outpatient age groups 18-44-year-old, >44-64-year-old and ≥ 65 -year-old, were >1000,
260 230, and 143 days, respectively (eFigure 5B). Compared to age-grouped outpatients, IgG $T_{1/2}$ of
261 inpatient age groups were slower, >1000 days for all 18-44-year-old, >44-64-year-old and ≥ 65 -
262 year-old age groups (eFigure 5C).

263 Next, we compared age-stratified neutralizing antibody titers across outpatients and
264 inpatients. In outpatient 18-44, >44-64 and ≥ 65 age-groups, neutralizing antibodies one-phase
265 decay $T_{1/2}$ were 16, 34, and 21 days, respectively (Figure 3A). Strikingly, we noted a higher
266 magnitude during early convalescence in outpatients ≥ 65 -years-old (GMT: 233 [95% CI: 111-
267 489]) compared to 18-44 (GMT: 67 [95% CI: 37-120], $P = 0.052$) and >44-64 (GMT: 80 [95% CI:
268 50-127], ($P = 0.037$) years-old groups (Figure 3B). However, this difference was not observed by
269 six months-post, correlating with the short $T_{1/2}$ in the ≥ 65 -years-old group (Figure 3B). The
270 slowest one-phase decay $T_{1/2}$ was observed in the inpatient ≥ 65 -years-old group, 84 days
271 (Figure 3C), and when comparing inpatient neutralizing antibodies during early convalescence,
272 higher GMT were observed in the >44-64 and ≥ 65 -years-old groups, 505 [95% CI: 346-738] ($P =$
273 0.14) and 328 [95% CI: 187-576] ($P = 0.18$), respectively (Figure 3D). These results appear to
274 suggest that the correlation between age and early humoral response is confounded by age-
275 specific severity of SARS-CoV-2 infection, consistent with other findings⁴⁵.

276

277 *Seasonal HCoV antibody responses are not correlated with COVID-19 outcomes or the*
278 *development of neutralizing antibodies*

279 We first explored whether subjects with PCR-confirmed SARS-CoV-2 infection
280 possessed higher levels of HCoV spike protein reactive antibodies as compared to SARS-CoV-
281 2 negative subjects. Higher levels of HCoV-OC43 and HCoV-HKU1 reactive IgG, but not of
282 HCoV-229E and HCoV-NL63 were observed in SARS-CoV-2-positive subjects during early
283 convalescence across age groups with mild to severe COVID-19 (Figure 4A). Further, we
284 identified a positive correlation and distinct clustering of maximum IgG levels between SARS-
285 CoV-2 and seasonal betacoronaviruses (HCoV-OC43 and HCoV-HKU1) that was related to
286 dpso (eFigure 6A-B), but only very weak relationships with the seasonal alphacoronaviruses
287 (HCoV-229E and HCoV-NL63) (eFigure 6C-D). To examine the clinical correlation between
288 HCoV antibody responses and COVID-19 severity, subjects were again stratified by age and
289 clinical phenotype; we observed no significant correlation with HCoV peak antibody responses
290 (Figure 4B). Finally, we sought to determine whether the induction of cross-reactive HCoV
291 antibodies following SARS-CoV-2 infection were associated with the magnitude or durability of
292 neutralizing antibodies to SARS-CoV-2. The magnitude of HCoV-OC43 and HCoV-HKU1 IgG
293 titers during early convalescence was not significantly associated with SARS-CoV-2 neutralizing
294 antibody responses during either early convalescence or six months-post symptom onset
295 (eFigure 7A-D).

296

297 **DISCUSSION**

298 In this study, we have demonstrated that SARS-CoV-2 binding IgG and neutralizing
299 antibodies remained detectable for up to one year in subjects following mild and moderate to
300 severe COVID-19. Further, we corroborated that the magnitude and durability of humoral
301 immune response are positively correlated, reflected by both $T_{1/2}$ and levels of binding IgG and
302 neutralizing antibody detected at time periods during early convalescence and six months-post

303 symptom onset^{46,47}. This may be due to robust stimulation of humoral immunity with failure to
304 control infection via innate responses.

305 Notably, when we controlled for hospitalization status, older age was positively
306 correlated with robust positive antibodies and neutralizing antibody responses. This suggests a
307 lack of immunosenescence driving waning humoral responses or seroreversion as all instances
308 of seroreversion between six to twelve months-post symptom onset occurred in outpatient
309 participants <65 years old (median age 30, Q1=26, Q3=43). Although, the association between
310 age and disease severity may confound this observation. The interaction between age, severity
311 and adaptive responses is complex^{48,49}; we noted that age ≥ 65 years was significantly
312 associated with the magnitude and durability of IgG responses for outpatients, whereas no
313 differences were found for inpatients across the age groups. However, sample size was smaller
314 in the inpatient group so this observation needs to be investigated further. Additionally, the
315 magnitude of the early neutralizing antibody response increased incrementally in outpatients
316 and inpatients age groups >44 years old. Interestingly, no significant differences in neutralizing
317 antibody levels were observed across age groups by six months after symptom onset.

318 When we assessed HCoV seroresponses in our cohort, we found no association with
319 the presence of antibodies to seasonal HCoVs and COVID-19 severity or with the development
320 of SARS-CoV-2 neutralizing antibodies. The induction of antibodies cross-reactive with HCoV
321 spike proteins after SARS-CoV-2 infection and boosted HCoV-HKU1 and HCoV-OC43
322 responses were observed, implying that highly conserved betacoronavirus spike protein
323 epitopes, possibly conformation-dependent, are cross-reactive⁵⁰. This conclusion is supported
324 by prior observations that conserved regions of the SARS-CoV-2 spike protein S2 subunit have
325 been shown to stimulate specific memory B cell repertoires^{51,52}. Although this investigation is
326 limited by the lack of baseline pre-SARS-CoV-2 infection sera, we also showed that boosted
327 HCoV-OC43 and HCoV-HKU1 memory responses were not associated with COVID-19 clinical
328 outcomes nor detrimental to the *de novo* development of SARS-CoV-2 neutralizing antibodies³⁰.

329 Our finding of variable waning yet persistent neutralization titers across participants
330 groups is consistent with other longitudinal studies^{7,53-55}, however neutralization presents only
331 one facet of long term SARS-CoV-2 immunity. Memory B cells specific to the SARS-CoV-2
332 spike receptor-binding domain, which are immunodominant and responsible for 90% of
333 neutralizing activity⁵⁶, have been detected even when circulating serum neutralizing antibodies
334 have waned below detectable limits^{7,55}.

335 Our results add to the growing body of literature that suggests humoral immunity
336 following natural infection with SARS-CoV-2 is long lived, including out to one year post-
337 infection. However, the magnitude and durability of SARS-CoV-2 antibody response was lower
338 and more variable in younger participants (<65 years old) who experienced less severe COVID-
339 19 and did not require hospitalization. These findings suggest that implementation of
340 vaccination against SARS-CoV-2 infection in all suitable populations, including those individuals
341 that have recovered from natural infection, would be prudent because vaccine induced immunity
342 to SARS-CoV-2 will likely be more long-lived than that elicited from mild COVID-19. Additional
343 studies will also be critical to further examine the protective role and durability of antibody
344 responses following SARS-CoV-2 re-infection and/or vaccination up to and beyond one year.

345

346

347 **DECLARATIONS**

348 This research protocol, IDCRP-085, was approved by the Uniformed Services University
349 Institutional Review Board.

350

351 **STATEMENT OF ETHICS**

352 The referenced human subjects protocol (IDCRP-085) was approved by the Uniformed Services
353 University Institutional Review Board and participating sites. All subjects or their legally
354 authorized representative provide written or verbal informed consent using approved documents

355 and procedures; the consent forms include clauses allowing use of specimens for investigations
356 including those conducted in this study.

357

358 **CONFLICT OF INTEREST**

359 None of the authors have any conflicts of interest of relevance to disclose.

360

361 **DISCLAIMER**

362 The contents of this publication are the sole responsibility of the author(s) and do
363 not necessarily reflect the views, opinions, or policies of the Uniformed Services University
364 (USU), the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF),
365 National Institutes of Health or the Department of Health and Human Services, Brooke Army
366 Medical Center, Naval Medical Center Portsmouth, Tripler Army Medical Center, Naval Medical
367 Center San Diego, Madigan Army Medical Center, Walter Reed National Military Medical
368 Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the
369 US Department of Defense (DoD), the Departments of the Air Force, Army or Navy, or the U.S.
370 Government. Mention of trade names, commercial products, or organization does not imply
371 endorsement by the U.S. Government. The investigators have adhered to the policies for
372 protection of human subjects as prescribed in 45 CFR 46. A number of the co-authors are
373 employees of the U.S. Government or military service members. This work was prepared as
374 part of their official duties. Title 17 U.S.C. §105 provides that 'Copyright protection under this
375 title is not available for any work of the United States Government.' Title 17 U.S.C. §101 defines
376 a U.S. Government work as a work prepared by a military service member or employee of the
377 U.S. Government as part of that person's official duties.

378

379

380 **FUNDING**

381 This project has been funded by the Defense Health Program, U.S. DoD, under awards
382 HU0001190002 and HU00012020067, and the National Institute of Allergy and Infectious
383 Diseases, National Institutes of Health, under award HU00011920111 and Inter-Agency
384 Agreement Y1-AI-5072.

385

386 **ACKNOWLEDGEMENTS**

387 We thank Dominic Esposito, Matthew Drew, Jennifer Melhako, Kelly Snead, Vanessa Wall,
388 John-Paul Denson, Simon Messing, and William Gillette (Protein Expression Lab, FNCLR) for
389 provision of HCoV-HKU1 and HCoV-OC43 spike proteins and excellent technical assistance.
390 Additionally, we thank Shreshta Phogat (USU, HJF) for technical assistance. We also thank the
391 members of the EPICC COVID-19 Cohort Study Group for their many contributions in
392 conducting the study and ensuring effective protocol operations. The following members were
393 all closely involved with the design, implementation, and oversight of the study.

394 *Brooke Army Medical Center, Fort Sam Houston, TX:* J. Cowden; D. Lindholm; A. Markelz; K.
395 Mende; T. Merritt; R. Walter; CPT T. Wellington

396 *Carl R. Darnall Army Medical Center, Fort Hood, TX:* MAJ S. Bazan

397 *Fort Belvoir Community Hospital, Fort Belvoir, VA:* L. Brandon; N. Dimascio-Johnson; MAJ E.
398 Ewers; LCDR K. Gallagher; LCDR D. Larson; MAJ M. Odom

399 *Henry M. Jackson Foundation, Inc., Bethesda, MD:* P. Blair; D. Clark

400 *Madigan Army Medical Center, Joint Base Lewis McChord, WA:* LTC C. Colombo; R. Colombo;
401 CPT C. Conlon; CPT K. Everson; LTC P. Faestel; COL T. Ferguson; MAJ L. Gordon; LTC S.
402 Grogan; CPT S. Lis; COL C. Mount; LTC D. Musfeldt; MAJ R. Sainato; C. Schofield; COL C.
403 Skinner; M. Stein; MAJ M. Switzer; MAJ M. Timlin; MAJ S. Wood

404 *Naval Medical Center Portsmouth, Portsmouth, VA:* G. Atwood; R. Carpenter; LCDR C.
405 Eickhoff; CAPT K. Kronmann; T. Lalani; LCDR T. Lee; T. Warkentien

406 *Naval Medical Center San Diego, San Diego, CA:* CAPT J. Arnold; CDR C. Berjohn; S.
407 Cammarata; LCDR S. Husain; LCDR A. Lane; CAPT R. Maves; J. Parrish; G. Utz

408 *Tripler Army Medical Center, Honolulu, HI:* S. Chi; MAJ E. Filan; K. Fong; CPT T. Horseman;
409 MAJ M. Jones; COL A. Kanis; LTC A. Kayatani; MAJ W. Londeree; LTC C. Madar; MAJ J.
410 Masel; MAJ M. McMahon; G. Murphy; COL V. Nguay; MAJ E. Schoenman; C. Uyehara; LTC R.
411 Villacorta Lyew

412 *Uniformed Services University of the Health Sciences, Bethesda, MD:* B. Agan; C. Broder;
413 CAPT T. Burgess; COL K. Chung; C. Coles; C. English; M. Haigney; COL P. Hickey; E. Laing;
414 LTC J. Livezey; A. Malloy; COL T. Oliver; E. Parmelee; S. Pollett; S. Richard; J. Rozman; M.
415 Sanchez; A. Scher; CDR M. Simons; A. Snow; D. Tribble

416 *United States Air Force School of Medicine, Dayton, OH:* A. Fries

417 *Walter Reed National Military Medical Center, Bethesda, MD:* A. Ganesan; D. Gunasekera; MAJ
418 N. Huprikar; M. Oyenehin

419 *William Beaumont Army Medical Center, El Paso, TX:* CPT M. Banda; CPT B. Davis; MAJ T.
420 Hunter; CPT O. Ikpeke-Magege; CPT S. Kemp; R. Mody; R. Resendez; COL M. Wiggins

421 *Womack Army Medical Center, Fort Bragg, NC:* B. Barton; D. Hostler; C. Maldonado

422

423

424

425

426 REFERENCES

- 427 1. Widge AT, Roupheal NG, Jackson LA, et al. Durability of Responses after SARS-CoV-2
428 mRNA-1273 Vaccination. *New England Journal of Medicine*. 2020;384(1):80-82.
- 429 2. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective
430 correlate for COVID-19 vaccines. *medRxiv*. 2021:2021.2003.2017.20200246.
- 431 3. Ripberger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological
432 Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable
433 Humoral Immunity. *Immunity*. 2020;53(5):925-933.e924.
- 434 4. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2
435 infection persist for months. *Science*. 2020;370(6521):1227-1230.
- 436 5. Choe PG, Kim K-H, Kang CK, et al. Antibody Responses 8 Months after Asymptomatic
437 or Mild SARS-CoV-2 Infection. *Emerging Infectious Disease journal*. 2021;27(3):928.
- 438 6. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2
439 infections. *Nature Communications*. 2021;12(1):63.
- 440 7. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for
441 up to 8 months after infection. *Science*. 2021;371(6529):eabf4063.
- 442 8. Glück V, Grobecker S, Tydykov L, et al. SARS-CoV-2-directed antibodies persist for
443 more than six months in a cohort with mild to moderate COVID-19. *Infection*. 2021:1-8.
- 444 9. Noh JY, Kwak JE, Yang JS, et al. Longitudinal assessment of anti-SARS-CoV-2 immune
445 responses for six months based on the clinical severity of COVID-19. *J Infect Dis*. 2021.
- 446 10. Zheng Y, Zhang Q, Ali A, et al. Sustainability of SARS-CoV-2 Induced Humoral
447 Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over
448 Six Months. *Viral Sin*. 2021:1-10.
- 449 11. Larson D, Brodnyak SL, Voegtly LJ, et al. A Case of Early Reinfection With Severe
450 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clinical Infectious
451 Diseases*. 2020.
- 452 12. Torres DA, Ribeiro L, Riello A, Horovitz DDG, Pinto LFR, Croda J. Reinfection of
453 COVID-19 after 3 months with a distinct and more aggressive clinical presentation: Case
454 report. *J Med Virol*. 2021;93(4):1857-1859.
- 455 13. Lee JS, Kim SY, Kim TS, et al. Evidence of Severe Acute Respiratory Syndrome
456 Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019. *Clin
457 Infect Dis*. 2020.
- 458 14. Alonso FOM, Sabino BD, Guimarães M, Varella RB. Recurrence of SARS-CoV-2
459 infection with a more severe case after mild COVID-19, reversion of RT-qPCR for
460 positive and late antibody response: Case report. *J Med Virol*. 2021;93(2):655-656.
- 461 15. Kim AY, Gandhi RT. Re-infection with SARS-CoV-2: What Goes Around May Come
462 Back Around. *Clin Infect Dis*. 2020.
- 463 16. Addetia A, Crawford KHD, Dingens A, et al. Neutralizing Antibodies Correlate with
464 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High
465 Attack Rate. *Journal of Clinical Microbiology*. 2020;58(11):e02107-02120.
- 466 17. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-
467 CoV-2 Infection in Health Care Workers. *New England Journal of Medicine*.
468 2020;384(6):533-540.
- 469 18. Schlickeiser S, Schwarz T, Steiner S, et al. Disease Severity, Fever, Age, and Sex
470 Correlate With SARS-CoV-2 Neutralizing Antibody Responses. *Front Immunol*.
471 2020;11:628971.

- 472 19. Trinité B, Tarrés-Freixas F, Rodon J, et al. SARS-CoV-2 infection elicits a rapid
473 neutralizing antibody response that correlates with disease severity. *Sci Rep*.
474 2021;11(1):2608.
- 475 20. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing
476 antibody responses in the three months following SARS-CoV-2 infection in humans.
477 *Nature Microbiology*. 2020;5(12):1598-1607.
- 478 21. Henss L, Scholz T, von Rhein C, et al. Analysis of Humoral Immune Responses in
479 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis*.
480 2021;223(1):56-61.
- 481 22. Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody
482 responses in a COVID-19 convalescent plasma donor population. *J Clin Invest*.
483 2020;130(11):6141-6150.
- 484 23. Hansen CB, Jarlhelt I, Pérez-Alós L, et al. SARS-CoV-2 Antibody Responses Are
485 Correlated to Disease Severity in COVID-19 Convalescent Individuals. *J Immunol*.
486 2021;206(1):109-117.
- 487 24. Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral immune
488 responses in convalescent patients following symptomatic COVID-19. *Nat Commun*.
489 2021;12(1):1813.
- 490 25. Röltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody
491 responses to SARS-CoV-2 infection associated with disease severity and outcome.
492 *Science Immunology*. 2020;5(54):eabe0240.
- 493 26. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of
494 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals
495 in Denmark in 2020: a population-level observational study. *Lancet*.
496 2021;397(10280):1204-1212.
- 497 27. Yang HS, Costa V, Racine-Brzostek SE, et al. Association of Age With SARS-CoV-2
498 Antibody Response. *JAMA Netw Open*. 2021;4(3):e214302.
- 499 28. Antibody Response After SARS-CoV-2 Infection and Implications for Immunity. *Annals*
500 *of Internal Medicine*.0(0):null.
- 501 29. Dugas M, Grote-Westrick T, Vollenberg R, et al. Less severe course of COVID-19 is
502 associated with elevated levels of antibodies against seasonal human coronaviruses OC43
503 and HKU1 (HCoV OC43, HCoV HKU1). *Int J Infect Dis*. 2021;105:304-306.
- 504 30. Anderson EM, Goodwin EC, Verma A, et al. Seasonal human coronavirus antibodies are
505 boosted upon SARS-CoV-2 infection but not associated with protection. *Cell*. 2021.
- 506 31. Sermet-Gaudelus I, Temmam S, Huon C, et al. Prior infection by seasonal coronaviruses,
507 as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children,
508 France, April to June 2020. *Euro Surveill*. 2021;26(13).
- 509 32. Guo L, Wang Y, Kang L, et al. Cross-reactive antibody against human coronavirus OC43
510 spike protein correlates with disease severity in COVID-19 patients: a retrospective
511 study. *Emerg Microbes Infect*. 2021;10(1):664-676.
- 512 33. Khan S, Nakajima R, Jain A, et al. Analysis of Serologic Cross-Reactivity Between
513 Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen
514 Microarray. *bioRxiv*. 2020.
- 515 34. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to
516 SARS-CoV-2 in humans. *Science*. 2020;370(6522):1339-1343.

- 517 35. Selva KJ, van de Sandt CE, Lemke MM, et al. Systems serology detects functionally
518 distinct coronavirus antibody features in children and elderly. *Nat Commun.*
519 2021;12(1):2037.
- 520 36. Majdoubi A, Michalski C, O'Connell SE, et al. A majority of uninfected adults show pre-
521 existing antibody reactivity against SARS-CoV-2. *JCI Insight.* 2021.
- 522 37. Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is associated
523 with less-severe COVID-19. *J Clin Invest.* 2021;131(1).
- 524 38. Laing ED, Sterling SL, Richard SA, et al. Antigen-based multiplex strategies to
525 discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human
526 coronavirus humoral responses. *medRxiv.* 2021.
- 527 39. Lalani T, Lee TK, Laing ED, et al. SARS-CoV-2 Infections and Serologic Responses
528 Among Military Personnel Deployed on the USNS COMFORT to New York City During
529 the COVID-19 Pandemic. *Open Forum Infect Dis.* 2021;8(2):ofaa654.
- 530 40. Clifton GT, Pati R, Krammer F, et al. SARS-CoV-2 Infection Risk Among Active Duty
531 Military Members Deployed to a Field Hospital - New York City, April 2020. *MMWR*
532 *Morb Mortal Wkly Rep.* 2021;70(9):308-311.
- 533 41. Neerukonda SN, Vassell R, Herrup R, et al. Establishment of a well-characterized SARS-
534 CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression
535 of ACE2 and TMPRSS2. *PLoS One.* 2021;16(3):e0248348.
- 536 42. Amanat F, White KM, Miorin L, et al. An In Vitro Microneutralization Assay for SARS-
537 CoV-2 Serology and Drug Screening. *Curr Protoc Microbiol.* 2020;58(1):e108.
- 538 43. RStudio Team (2020). RStudio: Integrated Development for R. RStudio P, Boston, MA
539 URL <http://www.rstudio.com/>.
- 540 44. Sholukh AM, Fiore-Gartland A, Ford ES, et al. Evaluation of SARS-CoV-2
541 neutralization assays for antibody monitoring in natural infection and vaccine trials.
542 *medRxiv.* 2020:2020.2012.2007.20245431.
- 543 45. Li K, Huang B, Wu M, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during
544 SARS-CoV-2 infection and recovery from COVID-19. *Nature Communications.*
545 2020;11(1):6044.
- 546 46. Ren L, Zhang L, Chang D, et al. The kinetics of humoral response and its relationship
547 with the disease severity in COVID-19. *Communications Biology.* 2020;3(1):780.
- 548 47. Mor M, Werbner M, Alter J, et al. Multi-clonal SARS-CoV-2 neutralization by
549 antibodies isolated from severe COVID-19 convalescent donors. *PLOS Pathogens.*
550 2021;17(2):e1009165.
- 551 48. Rydzynski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive
552 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
553 Severity. *Cell.* 2020;183(4):996-1012.e1019.
- 554 49. Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection
555 in hospitalized pediatric and adult patients. *Sci Transl Med.* 2020;12(564).
- 556 50. Sakharkar M, Rappazzo CG, Wieland-Alter WF, et al. Prolonged evolution of the human
557 B cell response to SARS-CoV-2 infection. *Sci Immunol.* 2021;6(56).
- 558 51. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to
559 SARS-CoV-2 in humans. *Science.* 2020;370(6522):1339-1343.
- 560 52. Song G, He WT, Callaghan S, et al. Cross-reactive serum and memory B cell responses
561 to spike protein in SARS-CoV-2 and endemic coronavirus infection. *bioRxiv.* 2020.

- 562 53. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody
563 responses and duration of immunity: a longitudinal study. *Lancet Microbe*. 2021.
564 54. Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of Neutralizing Antibody Titers
565 in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *The*
566 *Journal of Infectious Diseases*. 2020;223(2):197-205.
567 55. Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2
568 in mild-moderate COVID-19. *Nature Communications*. 2021;12(1):1162.
569 56. Piccoli L, Park YJ, Tortorici MA, et al. Mapping Neutralizing and Immunodominant
570 Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-
571 Resolution Serology. *Cell*. 2020;183(4):1024-1042.e1021.

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592 **TABLES**

593 **Table 1. Baseline characteristics of participants included in the longitudinal study of**
 594 **antibody responses.**

	Outpatient (N=192)	Inpatient (N=58)
Demographic Information		
Age group		
<18	6 (3.1%)	0 (0.0%)
18-44	94 (49.0%)	9 (15.5%)
>44-64	78 (40.6%)	33 (56.9%)
≥65	14 (7.3%)	16 (27.6%)
Gender		
Female	86 (44.8%)	25 (43.1%)
Male	106 (55.2%)	33 (56.9%)
Race		
Black	27 (14.1%)	18 (31.0%)
Hispanic	60 (31.2%)	19 (32.8%)
Other	20 (10.4%)	4 (6.9%)
White	85 (44.3%)	17 (29.3%)
Days post-symptom onset at collection		
(n = 764)*	52 (0 - 385)	53 (1 - 378)

595 *Median and range calculated based on days post-symptom onset at collection

596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606

607 **FIGURE LEGENDS**

608 **Figure 1. Evaluation of the magnitude and duration of the antibody response and COVID-**
609 **19 clinical phenotype.** Non-linear regressions were used to compare IgG responses from **(A)**
610 outpatients (n=192) and inpatients (n=58). Longitudinal samples for subjects are connected by
611 lines; second order polynomial curves were fit to inpatient (red) and outpatient (blue) groups;
612 95% CIs are shaded gray. A horizontal line indicates the indeterminate range between SARS-
613 CoV-2 positive (>4774) and negative (<4144) IgG; MFI, median fluorescence intensity. Two
614 distinct shaded regions highlighted early convalescence (yellow) and 6 months-post (pink)
615 windows. **(B)** Early convalescence (median 35 dpso), six months-post (median 188 dpso) and
616 twelve months-post (median 357 dpso) IgG responses were compared between outpatients and
617 inpatients; error bars indicate the geometric mean and 95% CI. **(C)** Longitudinal SNT
618 neutralizing antibody responses of outpatients (n=54) and inpatients (n=20). **(D)** Early
619 convalescence and six months-post SNT neutralizing antibodies were compared by
620 hospitalization status. *P*-values were determined by unpaired t-test with Welch's correction, α =
621 0.05; error bars indicate the geometric mean and 95% CI.


622
623 **Figure 2. The magnitude and durability of IgG-binding responses are associated with**
624 **COVID-19 severity and age.** **(A)** Multivariate linear regression analysis of outpatient and
625 inpatient IgG responses and **(B)** hospitalization status stratified by age groups, outpatients, 18-
626 44 (n=94), >44-64 (n=78), ≥ 65 (n=14), and inpatients, 18-44 (n=9), >44-64 (n=33), ≥ 65 (n=16)
627 during early convalescence. A horizontal line indicates cutoff for positive/negative IgG; MFI,
628 median fluorescence intensity. Statistical significance were determined by unpaired t-test with
629 Welch's correction, $\alpha = 0.05$; error bars indicate the geometric mean and 95% CI.
630 **(C-D)** Six months-post IgG responses were compared between age-stratified outpatients and
631 inpatients.

632


633 **Figure 3. The magnitude and durability of neutralizing antibody responses are associated**
634 **with COVID-19 severity and age. (A)** Longitudinal SNT measurement of neutralizing
635 antibodies in outpatient age groups, 18-44 (n=18), >44-64 (n=29) and ≥65 (n=6); longitudinal
636 samples are connected by lines, second order polynomial curves and 95% CIs are shaded gray.
637 **(B)** Early convalescence and six months-post SNT measured neutralizing antibodies compared
638 between outpatient age groups. **(C)** Longitudinal SNT measurement of neutralizing antibodies in
639 outpatient age groups, 18-44 (n=1), >44-64 (n=13) and ≥65 (n=6). **(D)** Early convalescence and
640 six months-post SNT measured neutralizing antibodies compared between inpatient age
641 groups. Statistical significance were determined by unpaired t-test with Welch's correction, $\alpha =$
642 0.05; error bars indicate the geometric mean and 95% CI.

643
644 **Figure 4. Seasonal HCoV antibody responses are not associated with COVID-19 clinical**
645 **outcomes. (A)** IgG binding levels of SARS-CoV-2 and seasonal HCoV-OC43, HCoV-HKU1,
646 HCoV-229E, HCoV-NL63 detected in SARS-CoV-2 PCR-positive (n=505) and SARS-CoV-2
647 PCR-negative (n=92) samples. **(B)** Stratified SARS-CoV-2 positive samples (n=505) into age
648 groups (18-44, >44-64, and ≥65 years old) and COVID-19 severity (outpatient vs. inpatient).
649 MFI, median fluorescence intensity; dpso is from zero to twelve months; boxplots denote
650 median, first quartile (25th percentile) and third quartile (75th percentile); statistical significance
651 was determined by unpaired t-test with Welch's correction, $\alpha = 0.05$.


652
653
654
655




A. Early convalescence




B. Early convalescence




Early convalescence




C. 6 months-post















D. 6 months-post




6 months-post







● outpatient ● inpatient

A. Age group 18-44**Age group >44-64****Age group ≥65****B. Early Convalescence****6 months-post****12 months-post****C. Age group 18-44****Age group >44-64****Age group ≥65****D. Early Convalescence****6 months-post****12 months-post**

A.**SARS-CoV-2****HCoV-OC43****HCoV-HKU1****HCoV-229E****HCoV-NL63**

 SARS-CoV-2 positive
  SARS-CoV-2 negative

B.**HCoV-OC43****HCoV-HKU1****HCoV-229E****HCoV-NL63**

 Outpatient
  Inpatient